CAR-T cells and BiTEs in solid tumors: challenges and perspectives
Abstract Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for the...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-021-01067-5 |
id |
doaj-2bbb8d605fec4173a17b12b48f0231fe |
---|---|
record_format |
Article |
spelling |
doaj-2bbb8d605fec4173a17b12b48f0231fe2021-04-25T11:03:31ZengBMCJournal of Hematology & Oncology1756-87222021-04-0114111210.1186/s13045-021-01067-5CAR-T cells and BiTEs in solid tumors: challenges and perspectivesJulien Edeline0Roch Houot1Aurélien Marabelle2Marion Alcantara3Medical Oncology, Centre Eugène Marquis, University of Rennes 1Department of Hematology, CHU Rennes, INSERM U1236, University of RennesDépartement d’Innovation Thérapeutique et d’Essais Précoces (DITEP), INSERM U1015, INSERM CIC1428, Université Paris SaclayCenter for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research UniversityAbstract Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their development in solid tumors. Nonetheless, the use of such new drugs to treat solid tumors is not straightforward. So far, the results from early phase clinical trials are not as impressive as expected but many improvements are under way. In this review we present an overview of the clinical development of CAR-T cells and BiTEs targeting the main antigens expressed by solid tumors. We emphasize the most frequent hurdles encountered by either CAR-T cells or BiTEs, or both, and summarize the strategies that have been proposed to overcome these obstacles.https://doi.org/10.1186/s13045-021-01067-5CAR-T cellsBiTEsBispecific antibodiesSolid tumors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Julien Edeline Roch Houot Aurélien Marabelle Marion Alcantara |
spellingShingle |
Julien Edeline Roch Houot Aurélien Marabelle Marion Alcantara CAR-T cells and BiTEs in solid tumors: challenges and perspectives Journal of Hematology & Oncology CAR-T cells BiTEs Bispecific antibodies Solid tumors |
author_facet |
Julien Edeline Roch Houot Aurélien Marabelle Marion Alcantara |
author_sort |
Julien Edeline |
title |
CAR-T cells and BiTEs in solid tumors: challenges and perspectives |
title_short |
CAR-T cells and BiTEs in solid tumors: challenges and perspectives |
title_full |
CAR-T cells and BiTEs in solid tumors: challenges and perspectives |
title_fullStr |
CAR-T cells and BiTEs in solid tumors: challenges and perspectives |
title_full_unstemmed |
CAR-T cells and BiTEs in solid tumors: challenges and perspectives |
title_sort |
car-t cells and bites in solid tumors: challenges and perspectives |
publisher |
BMC |
series |
Journal of Hematology & Oncology |
issn |
1756-8722 |
publishDate |
2021-04-01 |
description |
Abstract Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their development in solid tumors. Nonetheless, the use of such new drugs to treat solid tumors is not straightforward. So far, the results from early phase clinical trials are not as impressive as expected but many improvements are under way. In this review we present an overview of the clinical development of CAR-T cells and BiTEs targeting the main antigens expressed by solid tumors. We emphasize the most frequent hurdles encountered by either CAR-T cells or BiTEs, or both, and summarize the strategies that have been proposed to overcome these obstacles. |
topic |
CAR-T cells BiTEs Bispecific antibodies Solid tumors |
url |
https://doi.org/10.1186/s13045-021-01067-5 |
work_keys_str_mv |
AT julienedeline cartcellsandbitesinsolidtumorschallengesandperspectives AT rochhouot cartcellsandbitesinsolidtumorschallengesandperspectives AT aurelienmarabelle cartcellsandbitesinsolidtumorschallengesandperspectives AT marionalcantara cartcellsandbitesinsolidtumorschallengesandperspectives |
_version_ |
1721510089756508160 |